NGD-4715 is a drug developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1.[1] In animal models it has anxiolytic, antidepressant, and anorectic effects,[2] and it has successfully passed Phase I clinical trials in humans.[3]
 | |
| Identifiers | |
|---|---|
| CAS Number | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C25H30F3N3O3 |
| Molar mass | 477.528 g·mol−1 |
| 3D model (JSmol) | |
| |
Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among its key assets.[4] All four laboratories were closed and sold, and no employees were retained.[5]
The structure of NGD-4715 has been confused with for example 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine.[6]
References
edit- ^ Tarrant J, Hodgetts KJ, Chenard BL, Krause JE, Doller D (2017). "The Discovery of the MCH-1 Receptor Antagonist NGD-4715 for the Potential Treatment of Obesity". Comprehensive Medicinal Chemistry III. pp. 488–515. doi:10.1016/B978-0-12-409547-2.13785-0. ISBN 9780128032015.
- ^ Chaki S, Kanuma K (2007). "Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders". Drugs of the Future. 32 (9): 809. doi:10.1358/dof.2007.032.09.1131450.
- ^ "Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity". Business Wire. 2 May 2007.
- ^ "Neurogen acquired by Ligand Pharmaceuticals". Business Wire. 24 August 2009.
- ^ "Neurogen to sell Real Estate for $3.5m". Chicago Tribune. 10 November 2009.
- ^ "NGD-4715". PubChem. U.S. National Library of Medicine.
 | This article about an anxiolytic is a stub. You can help Wikipedia by expanding it. |